The Pathfinder retweeted
$IDYA IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint
•Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint
•IDE849 has demonstrated a 52.6% ORR (10/19), median PFS of 7.0 months, and an estimated 9-month OS rate of 82.4% in 2L+ NEC
•Global Phase 1/2 trial of IDE849 has shown a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) at the 2.4 mg/kg and 3.5 mg/kg expansion doses, respectively
•IDEAYA is targeting to initiate two randomized Phase 3 registrational trials in the refractory NEC and post-Imdelltra ES-SCLC settings, and a potential registration-enabling single-arm extension cohort in refractory GEP-NEC, by the end of 2026
The Pathfinder retweeted
It’s a privilege to be able to share our Atlas Venture 2026 Year In Review.
- Capital markets: Biotech is Back… we hope
- innovation industry: patient impact
- Atlas Venture: doing well by doing good
lifescivc.com/2026/11/atlas-…
The Pathfinder retweeted
$PEPG $125M offering priced at $5/share
$PEPG valuation still undemanding I think. good risk/reward from here.
1
4
884
$DCTH obviously a Q3 blowout. I think Q4 guidance is way too conservative given new starts. Love move into ICC (8x to 10x larger than mUm) w/ good historical evidence from IHP & CHEMOSTAT; cRc interim moved to mid 27 (from late 27); Believe CHOPIN add to NCCN still in cards
The Pathfinder retweeted
$VIR
$VIR came to kick some ass, apparently…
a back to de Backer PR:
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
$VIR
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
Editor: strong case to be made that $VIR is best in class/disease vis a vis $GILD, $MIRM
- Trial met all Phase 3 endpoints and regimen is well-tolerated with all patients completing 48 weeks of treatment
- 100% of patients achieved virologic response at Week 24 with 79% of patients reaching undetectable virus (as defined by HDV RNA TND) at Week 48
$xbi
The Pathfinder retweeted
Today, Xeris Biopharma announced financial results and business highlights for the third quarter ended September 30, 2026. To learn more, read the press release at bit.ly/4sH3SrN. $XERS
The Pathfinder retweeted
$AXSM Q3 results. globenewswire.com/news-relea…
The Pathfinder retweeted
"They’re orchestrating a wealth transfer. The stock didn’t even trade—they just gapped it down 20% while the market was closed." $INTC
The Pathfinder retweeted
"I don’t think the reaction is appropriate to the earnings outcome. Most likley are the Democrats trying to crash the market to get more votes." $INTC
The Pathfinder retweeted
Today we announced positive Phase 1 study results for two novel, non-opioid pain candidates targeting Nav1.7 and Kv7 and plans to advance both candidates to Phase 2 proof-of-concept studies.
Read the press release: investor.xenon-pharma.com/ne…
@IASPpain #WC2026
$AXSM with pretty heavy correction the last few weeks. added some today.
1
3
648
The Pathfinder retweeted
$ROIV first expansion test for Lisraya passes.
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
investor.roivant.com/news-re…




























